Published in Int J Clin Oncol on October 23, 2008
Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat (2010) 2.49
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer (2010) 1.48
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. Neoplasia (2011) 1.11
Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One (2013) 0.95
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med (2011) 0.90
BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer. Cancer Sci (2014) 0.81
Molecular portraits of human breast tumours. Nature (2000) 94.14
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
DNA topoisomerases. Annu Rev Biochem (1996) 9.48
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell (1999) 5.28
Triple negative tumours: a critical review. Histopathology (2008) 4.94
Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 4.80
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science (1999) 3.47
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res (2001) 2.76
Basal-like breast cancer and the BRCA1 phenotype. Oncogene (2006) 2.62
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst (2004) 2.49
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Nucleotide excision repair in mammalian cells. J Biol Chem (1997) 2.23
Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res (2004) 2.13
RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 2.11
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene (1999) 2.09
Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry (1993) 1.99
Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med (2006) 1.88
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat (2007) 1.84
Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res (2004) 1.83
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44
BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle (2006) 1.32
Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene (2001) 1.32
Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer (2003) 1.27
Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 1.22
Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol (2003) 1.20
DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol (1993) 1.19
Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol (2000) 1.18
Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res (2001) 1.14
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol (2003) 1.12
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res (2005) 1.08
Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol (2004) 1.02
BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment? Biochim Biophys Acta (2006) 0.98
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol (2002) 0.98
Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res (2006) 0.95
Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit (2008) 0.88
Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol (1994) 0.78
Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers. J Cancer Res Clin Oncol (2007) 0.77
[Effect of a new anticancer drug, docetaxel (RP56976), on human leukemia cell lines]. Gan To Kagaku Ryoho (1994) 0.75
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers. Cancer Lett (2008) 0.75
A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer (2007) 1.17
Prediction of hormone sensitivity for breast cancers. Breast Cancer (2009) 0.89
Small gastrointestinal stromal tumor of the stomach showing rapid growth and early metastasis to the liver. Dig Endosc (2010) 0.88
Mechanisms of estrogen receptor-α upregulation in breast cancers. Med Mol Morphol (2011) 0.85
Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol (2013) 0.84
Molecular basis of two-exon skipping (exons 12 and 13) by c.1248+5g>a in OXCT1 gene: study on intermediates of OXCT1 transcripts in fibroblasts. Hum Mutat (2013) 0.81
Development of MLPA for human ACAT1 gene and identification of a heterozygous Alu-mediated deletion of exons 3 and 4 in a patient with mitochondrial acetoacetyl-CoA thiolase (T2) deficiency. Mol Genet Metab (2013) 0.81
A neonatal-onset succinyl-CoA:3-ketoacid CoA transferase (SCOT)-deficient patient with T435N and c.658-666dupAACGTGATT p.N220_I222dup mutations in the OXCT1 gene. J Inherit Metab Dis (2010) 0.81
Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. Breast Cancer (2013) 0.76
C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis. Breast Cancer (2013) 0.76